These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

292 related articles for article (PubMed ID: 21831637)

  • 1. Structure-based design of new DHFR-based antibacterial agents: 7-aryl-2,4-diaminoquinazolines.
    Li X; Hilgers M; Cunningham M; Chen Z; Trzoss M; Zhang J; Kohnen L; Lam T; Creighton C; G C K; Nelson K; Kwan B; Stidham M; Brown-Driver V; Shaw KJ; Finn J
    Bioorg Med Chem Lett; 2011 Sep; 21(18):5171-6. PubMed ID: 21831637
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Increased hydrophobic interactions of iclaprim with Staphylococcus aureus dihydrofolate reductase are responsible for the increase in affinity and antibacterial activity.
    Oefner C; Bandera M; Haldimann A; Laue H; Schulz H; Mukhija S; Parisi S; Weiss L; Lociuro S; Dale GE
    J Antimicrob Chemother; 2009 Apr; 63(4):687-98. PubMed ID: 19211577
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structure-based design of new dihydrofolate reductase antibacterial agents: 7-(benzimidazol-1-yl)-2,4-diaminoquinazolines.
    Lam T; Hilgers MT; Cunningham ML; Kwan BP; Nelson KJ; Brown-Driver V; Ong V; Trzoss M; Hough G; Shaw KJ; Finn J
    J Med Chem; 2014 Feb; 57(3):651-68. PubMed ID: 24428639
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel dihydrofolate reductase inhibitors. Structure-based versus diversity-based library design and high-throughput synthesis and screening.
    Wyss PC; Gerber P; Hartman PG; Hubschwerlen C; Locher H; Marty HP; Stahl M
    J Med Chem; 2003 Jun; 46(12):2304-12. PubMed ID: 12773035
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design, synthesis and evaluation of 2,4-diaminoquinazolines as inhibitors of trypanosomal and leishmanial dihydrofolate reductase.
    Khabnadideh S; Pez D; Musso A; Brun R; Pérez LM; González-Pacanowska D; Gilbert IH
    Bioorg Med Chem; 2005 Apr; 13(7):2637-49. PubMed ID: 15755663
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibitory properties and X-ray crystallographic study of the binding of AR-101, AR-102 and iclaprim in ternary complexes with NADPH and dihydrofolate reductase from Staphylococcus aureus.
    Oefner C; Parisi S; Schulz H; Lociuro S; Dale GE
    Acta Crystallogr D Biol Crystallogr; 2009 Aug; 65(Pt 8):751-7. PubMed ID: 19622858
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structural comparison of chromosomal and exogenous dihydrofolate reductase from Staphylococcus aureus in complex with the potent inhibitor trimethoprim.
    Heaslet H; Harris M; Fahnoe K; Sarver R; Putz H; Chang J; Subramanyam C; Barreiro G; Miller JR
    Proteins; 2009 Aug; 76(3):706-17. PubMed ID: 19280600
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Indole naphthyridinones as inhibitors of bacterial enoyl-ACP reductases FabI and FabK.
    Seefeld MA; Miller WH; Newlander KA; Burgess WJ; DeWolf WE; Elkins PA; Head MS; Jakas DR; Janson CA; Keller PM; Manley PJ; Moore TD; Payne DJ; Pearson S; Polizzi BJ; Qiu X; Rittenhouse SF; Uzinskas IN; Wallis NG; Huffman WF
    J Med Chem; 2003 Apr; 46(9):1627-35. PubMed ID: 12699381
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthesis and biological evaluation of N-acylhydrazones as inhibitors of MurC and MurD ligases.
    Sink R; Kovac A; Tomasić T; Rupnik V; Boniface A; Bostock J; Chopra I; Blanot D; Masic LP; Gobec S; Zega A
    ChemMedChem; 2008 Sep; 3(9):1362-70. PubMed ID: 18651694
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dihydrofolate reductase inhibitors as antibacterial agents.
    Hawser S; Lociuro S; Islam K
    Biochem Pharmacol; 2006 Mar; 71(7):941-8. PubMed ID: 16359642
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structure-based design and synthesis of lipophilic 2,4-diamino-6-substituted quinazolines and their evaluation as inhibitors of dihydrofolate reductases and potential antitumor agents.
    Gangjee A; Vidwans AP; Vasudevan A; Queener SF; Kisliuk RL; Cody V; Li R; Galitsky N; Luft JR; Pangborn W
    J Med Chem; 1998 Aug; 41(18):3426-34. PubMed ID: 9719595
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery of bacterial NAD+-dependent DNA ligase inhibitors: optimization of antibacterial activity.
    Stokes SS; Huynh H; Gowravaram M; Albert R; Cavero-Tomas M; Chen B; Harang J; Loch JT; Lu M; Mullen GB; Zhao S; Liu CF; Mills SD
    Bioorg Med Chem Lett; 2011 Aug; 21(15):4556-60. PubMed ID: 21719282
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthesis and in vitro antibacterial activity of 7-(3-alkoxyimino-4-amino-4-methylpiperidin-1-yl) fluoroquinolone derivatives.
    Wang JX; Zhang YB; Liu ML; Wang B; Chai Y; Li SJ; Guo HY
    Eur J Med Chem; 2011 Jun; 46(6):2421-6. PubMed ID: 21481984
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthesis and biological activity of novel antibacterial quinazolines.
    Bedi PM; Kumar V; Mahajan MP
    Bioorg Med Chem Lett; 2004 Oct; 14(20):5211-3. PubMed ID: 15380229
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design, synthesis, and antibacterial activities of novel 3,6-bicyclolide oximes: length optimization and zero carbon linker oximes.
    Tang D; Gai Y; Polemeropoulos A; Chen Z; Wang Z; Or YS
    Bioorg Med Chem Lett; 2008 Sep; 18(18):5078-82. PubMed ID: 18762418
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design, synthesis, and structure-activity relationship studies of conformationally restricted mutilin 14-carbamates.
    Fu L; Liu X; Ling C; Cheng J; Guo X; He H; Ding S; Yang Y
    Bioorg Med Chem Lett; 2012 Jan; 22(2):814-9. PubMed ID: 22209487
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel pyrazole derivatives as potent inhibitors of type II topoisomerases. Part 1: synthesis and preliminary SAR analysis.
    Gomez L; Hack MD; Wu J; Wiener JJ; Venkatesan H; Santillán A; Pippel DJ; Mani N; Morrow BJ; Motley ST; Shaw KJ; Wolin R; Grice CA; Jones TK
    Bioorg Med Chem Lett; 2007 May; 17(10):2723-7. PubMed ID: 17368897
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design, synthesis, antibacterial activity and docking study of some new trimethoprim derivatives.
    Rashid U; Ahmad W; Hassan SF; Qureshi NA; Niaz B; Muhammad B; Imdad S; Sajid M
    Bioorg Med Chem Lett; 2016 Dec; 26(23):5749-5753. PubMed ID: 28327306
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Water-soluble pleuromutilin derivative with excellent in vitro and in vivo antibacterial activity against gram-positive pathogens.
    Hirokawa Y; Kinoshita H; Tanaka T; Nakata K; Kitadai N; Fujimoto K; Kashimoto S; Kojima T; Kato S
    J Med Chem; 2008 Apr; 51(7):1991-4. PubMed ID: 18330977
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery of pyrazolthiazoles as novel and potent inhibitors of bacterial gyrase.
    Ronkin SM; Badia M; Bellon S; Grillot AL; Gross CH; Grossman TH; Mani N; Parsons JD; Stamos D; Trudeau M; Wei Y; Charifson PS
    Bioorg Med Chem Lett; 2010 May; 20(9):2828-31. PubMed ID: 20356737
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.